Industry Coverage
Antonella Solidoro
Financial Analyst
T: +33 (0)1 4770 3024
Email
Sales Contact

T: +33 1 8362 9036
Email

Alert on Reports Published
Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

Subscribe

Follow the sector on Twitter

Epsilon Research covers the M&A transactions for the "Pharmaceuticals & Cosmetics R&W" industry [79 EMAT Reports], which includes:

 

Our analysts publish transaction multiples reports for private company M&A deals (announced 2004 onwards).

Each report presents detailed information on the deal value, structure and rationale, the target's activity, history and financial information; it includes the calculation of the key historic and current multiples: enterprise value over sales (EV/S), EBITDA (EV/EBITDA), or EBIT (EV/EBIT), P/E and Price to Book. All information sources are systematically given and company financials are carefully verified and restated if needed.

 

The reports are a unique source of information to have a comparable metric for the valuation of a private company, establish the "market value" of an investment or private equity investment portfolios.

 

The deal reports are published in Epsilon's EMAT database.
For an example of EMAT report, please click on this link.
If you wish to buy an EMAT Report, and you are not a customer, please contact us.

 

Recent M&A Deal Reports Published on EMAT

Date Acquirer Target Country Industries Valuation multiples See details
16/01/2024 Private Group led by Ardian Healthy Group (Aprium) Hauts-De-Seine Drugs Retailers * 119963
04/01/2024 L'Occitane International Dr. Vranjes Firenze Italy Personal Products, Cosmetics & Perfumes ** 115896
21/12/2023 Groupe Laf Santé Magdaléon Bas-Rhin Drugs Retailers ** 120860
01/11/2023 Private Group backed by Arcola Golden Naturals Netherlands e-commerce (B2C), Drugs Retailers, Food Complements * 117948
23/10/2023 LloydsPharmacy Ireland Kalamunda Ireland Drugs Retailers * 115321
06/07/2023 Series B funding round backed by Nextstage AM Mediprix Hérault Drugs Retailers * 113575
13/04/2023 Groupe Laf Santé Elsker Group Nord Drugs Retailers * 120884
21/11/2022 UniPhar BModesto Netherlands Drugs Retailers ** 110851
02/10/2022 Boticinal Ceido (Centre Européen d’Intérêt et de Développement de l’Officine) Paris Drugs Retailers * 111449
20/09/2022 UniPhar LXV Remedies Holdings (McCauley Pharmacy Group) Ireland Drugs Retailers * 110405
01/08/2022 Private Group led by Literacy Capital Ashleigh & Burnwood England Cosmetics & Perfumes *** 117337
02/07/2022 Private Group led by Latour Capital Groupe Laf Santé Haute-Garonne Drugs Retailers, Eyewear (retail) * 119979
06/03/2022 Groupe Laf Santé Gêner'+ (Pharmacorp) Haute-Garonne Drugs Retailers * 120898
02/12/2021 Boticinal Dynamis Santé Bas-Rhin Drugs Retailers * 111429
08/07/2021 Colruyt Group Newpharma Belgium e-commerce (B2C), Pharmaceuticals & Cosmetics R&W ** 108140
02/03/2021 MHP DXB Adam Myers England Drugs Retailers ** 110483
25/02/2021 Private group led by Isatis Capital, BNP Paribas Développement Sagitta Pharma (T&J Healthcare) Indre-Et-Loire Drugs Retailers * 107980
11/02/2021 Private Group led by Nobel Capital Partners Vitaminstore Online Netherlands e-commerce (B2C), Drugs Retailers ** 117940
26/11/2020 Medios Cranach Pharma Germany Drugs Retailers ** 110471
01/09/2020 UniPhar Hickey's Pharmacy Group Ireland Drugs Retailers ** 110427
About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

EMAT Database
Epsilon Multiple Analysis Tool
The Reference Source for Private Company Acquisition Multiples

Test & Subscribe
EMAT Report

► Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

 

► Example of EMAT Report